Loading...

Entera Bio Ltd.

ENTX•NASDAQ
HealthcareBiotechnology
$1.95
$-0.01(-0.51%)

Entera Bio Ltd. (ENTX) Stock Overview

Explore Entera Bio Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
0.00%
Profit Growth
$-0.11
↓ 7.33%
EPS Growth
$-0.11
↑ 19.35%
Operating Margin
-3373.54%
↓ 7.81%
ROE
-46.72%
↓ 7.33%
Dividend Yield
0.00%
Analyst Recommendations data is not available for ENTXAnalyst Recommendations details for ENTX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

CEO

Ms. Miranda J. Toledano M.B.A.

Employees

18

Headquarters

Kiryat Hadassah Minrav Building, Jerusalem

Founded

2018

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.